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ABSTRACT 
RP-HPLC method was developed for the determination of Omeprazole (OME) & Aspirin (ASP) in bulk and dosage form. Mobile 
phase use for the separation of OME & ASP is methanol and 0.05%OPA in water (pH= 3.5) with ratio of 60:40. The Colum used as 
C18 (Cosmosil) 4.6×150mm and flow rate 0.7mL/min. UV detector is used and the detection wavelength is 231nm. Retention time of 
OME and ASP are 4.61 & 8.03 min, respectively. This method was validated as per ICH guidelines. Linearity was observed at 10-
50µg/mL of OME and 20-100µg/mL of ASP. The % RSD is found to be less than 2%.The resolution between OME and ASP is 
11.55 and the tailing factors of both are less than 2.0.Therotical plates for OME and ASP are 5060, and 9367, respectively. Total run 
time is 15min. The developed RP-HPLC method was accurate, precise, selective and rapid for simultaneous estimation of 
Omeprazole and Aspirin in the pharmaceutical dosage form.” 
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INTRODUCTION 
YOSPRALA is a combination of aspirin, an anti-platelet 
agent, and omeprazole, a proton pump inhibitor (PPI), 
indicated for patients who require aspirin for secondary 
prevention of cardiovascular and cerebrovascular events 
and who are at risk of developing aspirin associated 
gastric ulcers.   
Reducing the combined risk of death and nonfatal stroke 
in patients who have had ischemic stroke or transient 
ischemia of the brain due to fibrin platelet emboli,   
• Reducing the combined risk of death and nonfatal MI 
in patients with a previous MI or unstable angina 
pectoris,  
 • Reducing the combined risk of MI and sudden death 
in patients with chronic stable angina pectoris, 
 • Use in patients who have undergone revascularization 
procedures (Coronary Artery Bypass Graft [CABG] or 
Percutaneous Transluminal Coronary Angioplasty 
[PTCA]) when there is a pre-existing condition for 
which aspirin is already indicated.   
The omeprazole component of YOSPRALA is indicated 
for decreasing the risk of developing aspirin associated 
gastric ulcers in patients at risk for developing aspirin-
associated gastric ulcers due to age (≥ 55) or 
documented history of gastric ulcers.  
The aim of the present work was to develop simple, 
economic, accurate, specific and precise RP-HPLC 
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methods for simultaneous estimation of omeprazole and 
aspirin in bulk drugs and combined pharmaceutical 
formulation and validation of newly developed 
analytical method. 
Omeprazole is use proton pump inhibitor (Antacid), 
chemically (4-methoxy-3,5-dimethylpyridyl,5-
methoxybbenzimidazol.Litreature survey of omeprazole 
has been estimated by UV, HPLC, HPTLC, RP-HPLC. 
 
Figure 1: Omeprazole 
Aspirin is use as antithrombotic, antianginal, antipyretic 
and anti-inflammatory agent chemically (2-
Acetoxybenzoic acid) aspirin is a use to lower risk to 
heart attack, artery disease 
1, 2, 3, 4 
 
Figure 2: Aspirin 
 
MATERIALS AND METHODS 
Instrument and equipment  
1. RP-HPLC –Yonglin acme 9000 
2. Sonicator-   Vensor 
3. UV Spectroscopy- Shimatzu 2080 
Materials 
1. Aspirin-Aspirin (AR grade) gifted sample from Sci-
tech laboratory Musalgaon, MIDC, Sinner, Nashik . 
2. Omeprazole-(AR grade) gifted sample from sci-tech 
laboratory Musalgaon MIDC, Sinner, Nashik. 
3. Methanol-HPLC grade methanol purchase from 
Merck ltd, Mumbai. 
4. Ortho phosparic acid water- 0.1mL OPA in 200mL 
water.(0.05%) 
Methods 
Identification of Aspirin & Omeprazole
 4 
Melting point was determined using digital melting point 
apparatus with one end open capillary method. The 
reference melting point of aspirin and omeprazole is 
136
o
C and 156
o
C respectively. 
Determination of wavelength maxima 
5, 6
 
Both the standard solution was scanned between 400nm 
to 200nm.The overlain spectrum of both drugs was 
recorded. From the overlain spectrum, 297nm (λmax of 
omeprazole) and 222 nm (λmax of Aspirin) were 
selected for estimation of drugs and the isobestic point 
was found to be at 231 nm and it is shown in fig 3 
 
     
                  -UV of Aspirin                          -UV of Omeprazole 
Figure 3: Isobestic point of Omeprazole & Aspirin 
Name of sample  Wavelength Absorbance 
Omeprazole 297nm 0.3698 
Aspirin 222nm 0.4408 
Isobestic Omeprazole 
& Aspirin 
231nm 0.3230 
 
Sarode et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(5):322-328          
ISSN: 2250-1177                                                                             [324]                                                                             CODEN (USA): JDDTAO 
Selection of chromatographic mode 
Proper selection of the method depend upon the nature 
of the sample (ionic, ionisable and neutral, its molecular 
weight and solubility. Both the drugs are freely soluble 
in organic. Hence, reversed phase HPLC was selected 
for the initial separations because of its simplicity and 
suitability. 
Selection of Mobile phase 
Omeprazole and Aspirin are freely soluble in HPLC 
grade of methanol. Not freely soluble in 
orthophosphoric acid and used uitrasonication. Both 
drugs are soluble in methanol and orthophosphoric acid. 
 
Mobile Phase 60+40 (Methanol+(0.05%) OPA) 
Selection of 
column 
4.6×150mm 
Wavelength  231nm 
Flow rate  0.7ml/min 
Column temp Ambient  
Sample size 20µL 
Retention time  4.61 omeprazol,8.35 aspirin  
Conclusion   Satisfactory Resolution, 
Theoretical Plate, Tailing Factor. 
 
RESULT AND DISCUSSION 
Orthophosparic acid water - 0.1mL OPA in 200mL 
water. (0.05%) 
Preparation of stock solution   
Accurately weighed of Omeprazole 10mg and 20mg 
Aspirin was taken in 10mL volumetric flask and 
dissolved in 10 mL methanol. To get standard stock 
solution.1000 µg/mL Omeprazole and 2000 µg/mL 
Aspirin. STOCK -I 
Preparation of mobile phase 
Pipette out 60 ml of concentrated methanol and 40 ml of 
0.05% OPA make up the volume up to 100ml and 
Sonicate 5 min. 
1) Take 0.1mL from the stock I and make up the volume 
with mobile   Phase 10 mL     = 10 µg/mL Omeprazole 
and 20 µg/mL Aspirin. 
2) Take 0.2 mL from the stock I and make up the 
volume with mobile   Phase 10 mL = 20 µg/mL 
Omeprazole and 40 µg/mL Aspirin. 
3) Take 0.3 mL from the stock I and make up the 
volume with mobile   Phase 10 mL     = 30 µg/mL 
Omeprazole and 60 gm/mL Aspirin. 
4) Take 0.4 mL from the stock I and make up the 
volume with mobile   Phase 10 mL     = 40 µg/mL 
Omeprazole and 80 µg/mL Aspirin. 
5) Take 0.5 mL from the stock I and make up the 
volume with mobile   Phase 10 mL     = 50 µg/mL 
Omeprazole and 100 µg/mL Aspirin. 
 
Figure 4: Chromatogram of Ome & Asp 
Table 1: Final chromatographic conditions 
Peak 
Name 
Retentio
n time 
Area  Plate 
count  
T F 
Ome  4.6167 507.77 5060.1 1.1297 
Asp 8.0333 1753.2 9367.1 1.3266 
 
Tab solution Preparation: 
Brand Name: Yosprala 
Weigh and finely powder 20 tablets. Accurately weigh 
and transfer a quantity of powder sample equivalent to 
10mg of Omeprazole and 20mg of Aspirin into a 10 ml 
clean dry volumetric flask, add 10ml methanol and 
sonicate to dissolve it completely and make volume up 
to the mark with the diluents(1000 µg/mL Ome and 
2000 µg/mL. From these solutions 0.1ml was pipette out 
and transferred into 10ml volumetric flask and makeup 
the volume up to the mark with methanol & 
Orthophosphoric acid (10 µg/mL Omeprazole and 20 
µg/mL Aspirin) and measured the absorbance at 231nm. 
The % purity of the drug was calculated by comparing 
the absorbance of test solution with standard. 
Tab Assay 
7,8 
0.4 ml from tab stock and make up 10 ml with mobile 
phase and produced 40 µg/mL Ome + 80 µg/mL Asp for 
assay 
 
Sarode et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(5):322-328          
ISSN: 2250-1177                                                                             [325]                                                                             CODEN (USA): JDDTAO 
 
Figure 5: Chromatogram for Assay 
 
Table 2: Assay 
Name  RT(min) TP TF Area  
Ome  4.7667 3827.0 1.33 1265.54 
Asp  8.1333 9876.3 1.37 5033.44 
 
Validation Parameter 
9,10,11,12 
Linearity:-The con. of ome and asp solution take in 
different concentration respect.10-50ug/mL, 20-
100ug/mL. At selected wavelength 231nm.  
 
Figure 6: Linearity 50 µg/mL Ome & 100 µg/mL 
 
Peak 
Name 
Retention 
time 
Area  Plate 
count  
T F 
Ome  4.6000 1230.7 5503.1 1.1472 
Asp 8.0167 5042.1 9537.0 1.1699 
 
Accuracy: The accuracy of an analytical method is the 
closeness of test results obtained by that method to the 
true value. The three triplicates of stock solution of 
Omeprazole and Aspirin equivalent to 10ppm, 20ppm, 
30ppm and 20ppm, 40ppm, 60ppm respectively were 
preparing by using standard solution. From stock 
solution aliquots of Ome and Aspirin 0.1 ml, 0.2ml, 
0.3ml were taken and diluted to 10ml mobile phase with 
diluted such that the final concentration of Ome-10, 20, 
30 µg/mL and Aspirin-20, 40, 60 µg/mL.
 
 
Figure 7: Chromatogram of accuracy Omeprazole 30µg/mL Aspirin 60 µg/mL. 
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Table 3: Accuracy of Omeprazole 
Conc. 
(μg/ml) 
Standard Deviation %RSD 
Area 
Mean 
 
 
SD 
%RSD 
 10 288.91 2.63 0.91 
20 525.86 7.71 1.47 
30 778.18 3.34 0.43 
 
Table 4: Accuracy of Aspirin 
Conc. 
(μg/ml) 
Standard Deviation %RSD 
Area 
Mean 
 
 
SD 
RSD 
     20 706.42 5.03 0.71 
     40 1741.04 7.25 0.99 
     60 2863.04 3.78 0.13 
  
Precision:-The precision intraday and inter day 
Precision system result showed good reproducibility. 
Intraday precision study was carried out by preparing 
drug solution from stock solution, aliquots of 
Omeprazole and Aspirin 0.2,  0.3, 0.4 ml were taken an 
diluted to 10 ml with diluents such that the final 
concentration of  Ome-20, 30, 40 µgm/mL and Asp-40, 
60, 80 µg/mL and analyzed. The same procedure was 
followed for second day also to determine inter-day 
precision. 
Table 5: Intra-day precision 
Conc 
µg/mL 
Area 
Mean  
SD %Amt 
Found 
% 
RSD 
OME     
20 530.32 6.74 100.42 1.27 
30 748.75 6.60 97.98 0.88 
40 996.01 5.40 99.84 0.54 
ASP     
40 1765.1 10.9 99.87 0.58 
60 2880.9 6.19 100.95 0.22 
80 3913.4 1.44 98.58 0.21 
 
 
Figure 8: Precision-20ug/ml and 40ug/ml Intra-day 
 
 
 
 
 
Table 6: Inter day precision 
Conc. 
ug/ml 
Area 
Mean  
SD %Amt 
Found 
% 
RSD 
OME     
20 530.32 6.74 100.42 1.27 
30 763.32 4.88 100.15 1.57 
40 996.01 5.40 99.84 0.54 
ASP     
40 1765.5 10.1 99.87 0.58 
60 2880.9 6.19 100.95 0.22 
80 3913.4 1.44 99.58 0.04 
 
 
Figure 9: Precision-20ug/mL and 40ug/ml interday 
 
% Recovery 
13,14 
The recovery of an analytical method is determined by 
applying the method to analyzed samples to which 
known amounts of analyte have been added. The 
Recovery is calculated from the test results as the 
percentage of analyte recovered by the assay. Three 
replicate injections, each of three different test 
concentrations in the range of 80%, 100% and 120% of 
labeled claim of tablet under study yielded the result 
within 98 to 102% of true concentration of each drug. 
The results indicated that the method is accurate. 
Table 7: Statistical Validation of Recovery Studies 
Ome and Asp 
Level of 
Recovery 
(%) 
Drug 
Mean % 
Recovery 
Standard 
Deviation 
% 
RSD 
80% 
Ome 98.20  1.70 1.73 
Asp 99.10  0.75 0.64 
100% 
Ome 101.16  1.78 0.44 
Asp 100.75  1.51 0.27 
120% 
Ome 101.58  1.07 0.37 
Asp 99.23  0.41 0.11 
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Figure 10: Recovery 120 % 
Robustness 
16 ,17 
The robustness of an analytical method is a measure of 
its capacity to remain unaffected by small but deliberate 
variations in method parameters and provides an 
indication of its reliability during normal usage. To 
verify the robustness of the method, the analysis was 
done under variables flow rate, mobile phase ratio and 
wavelength.  
System suitability parameter 
The system was evaluated by analyzing repeatability, 
retention time, tailing factor and theoretical plats of the 
column. 
Table 8: Robustness study of Ome & Asp 
Parameter 
change  
Conc. 
ug/ml 
Amt. 
Mean±SD 
%RSD 
Flow rate 
0.6ml 
32 1217.7±5.69 0.88 
0.8ml 32 1812.21±4.68 0.26 
69ml+31ml 
Me+OPA 
32 2099.53±24.9 1.19 
59ml+41ml 
Me+OPA 
32 1320.56±7.42 0.56 
230nm 32 2099.53±5.69 0.47 
232m 32 1855.70±32.8 1.77 
 
 
Figure 11: Change in wavelength 230 nm. 
 
Figure 12: Change in wavelength 232 nm. 
 
Limit of Detection (LOD) 
The LOD is the lowest limit that can be detected. Based 
on the S.D. of the response and the slope. The limit of 
detection (LOD) may be expressed as: 
LOD = 3.3 (SD)/S 
 
Where, SD= Standard deviation of the Y intercept 
S = Slope 
LOD = 3.3 x 4.65/ 23.46 = 0.5946 (µg/ml) (Omeprazole) 
LOD = 3.3 x 8.81/ 54.08 = 0.5375 (µg/ml) (Aspirin) 
The LOD of Omeprazole and Aspirin was found to be 
0.5946 (µg/ml) and 0.5375 (µg/ml) respectively. 
Limit of Quantitation 
The LOQ is the lowest concentration that can be 
quantitatively measured. Based on the S.D. deviation of 
the response and the slope. 
The quantitation limit (LOQ) may be expressed as 
LOQ = 10 (SD)/S 
Where, SD = standard deviation of Y intercept 
S = Slope 
LOQ = 10 x 4.65/23.46 = 1.9820     (µg/ml 
(Omeprazole) 
LOQ = 10 x 8.81/54.08 = 1.6290      (µg/ml (Aspirin) 
The LOQ of Omeprazole and Aspirin was found to be 
1.9820 (µg/mL) and 1.6290 (µg/mL) respectively. 
Summary of validation parameter 
 
Parameter (Unit) Ome Asp Accep. Criteria 
Linearity range (µg/ ml) 10-50  20-100 ----- 
Correlation Coefficient 0.9995  0.9987 0.999 
% Recovery 98.20-101.58%  99.10- 99.23% 98%- 102% 
Precision 
%RSD 
Intraday 1.27%  0.58 %  
% RSD NMT 2 Inter day 1.27%  0.58 % 
Robustness Robust  Robust Robust 
LOD 0.5946  μg /ml  0.5375 μg /ml NMT 2 
LOQ 1.9820  μg /ml  1.6290 μg/ ml NMT 2  
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CONCLUSION 
RP-HPLC method has been developed for the 
simultaneous estimation of Omeprazole and Aspirin. 
These methods have good resolution both the drugs 
good and short analysis time. Literature survey revealed 
that several methods have been reported for 
determination of Omeprazole and Aspirin individually 
or in combination with other drugs in pharmaceutical 
dosage forms. The developed method was validated. It 
was found to be simple, precise, accurate and robust. 
The proposed method can be used for routine analysis of 
omeprazole and Aspirin in combined dosage form.  
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